MORRISTOWN, N.J., March 9, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a global integrated pharmaceutical company, announced today that David A. Buchen has been promoted to Executive Vice President, General Counsel and Secretary, and R. Todd Joyce has been promoted to Executive Vice President, Chief Financial Officer. Both continue to report to Paul M. Bisaro, President and Chief Executive Officer.
"These promotions not only recognize the substantial individual contributions David and Todd have made to Watson's ongoing success, but also the significant achievements made by both in building the teams that support our Company's global growth," said Bisaro. "With the increasing complexity of our global portfolio – generics, brands and biologics – our international legal team has been increasingly called upon under David's leadership to support a broad array of competitive, compliance and intellectual property legal activities. Todd and his team have ensured the seamless integration of our global finance operations following the Arrow acquisition, and demonstrated the leadership required to manage our global finances which have allowed us to deliver on our financial commitments while maintaining our capacity for continued growth and expansion. Both promotions are well deserved and reflect the importance of these functions and the role of these two leaders in our success."
Mr. Joyce was appointed Senior Vice President, Chief Financial Officer of Watson in October 2009. He joined Watson in 1997 as Corporate Controller and was named Vice President, Corporate Controller and Treasurer in 2001. During the periods October 2006 to November 2007 and from July 2009 until October 2009, Mr. Joyce served as interim Principal Financial Officer.
Prior to joining Watson, Mr. Joyce served as Vice President of Tax from 1992
|SOURCE Watson Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved